Skip to main content
. 2019 May 31;11:429–441. doi: 10.2147/CLEP.S204322

Table S2.

Dose–response associations between the use of individual NSAIDs and the risk of all-cause mortality in patients with end-stage renal disease

Cumulative NSAID use Number of mortality Person-years Incidence rate (95% CI) (per 100 person-years) Crude HR(95% CI) Adjusted HR (95% CI)
Diclofenac
0 DDDs (0 g) 810 9967 8.1 (7.6–8.7) 1.00 (reference) 1.00 (reference)
1−30 DDDs (0.1−3 g) 599 5656 10.6 (9.8–11.5) 1.34 (1.19–1.50) 1.44 (1.29–1.62)
31−90 DDDs (3.1−9 g) 77 851 9.1 (7.2–11.3) 1.17 (0.92–1.50) 1.28 (1.00–1.64)
>90 DDDs (>9 g) 29 231 12.6 (8.7–18.1) 1.68 (1.15–2.45) 1.95 (1.33–2.86)
Celecoxib
0 DDDs (0 g) 1170 14267 8.2 (7.7–8.7) 1.00 (reference) 1.00 (reference)
1−30 DDDs (0.2−6 g) 222 1565 14.2 (12.4–16.2) 1.77 (1.53–2.05) 1.68 (1.44–1.95)
31−90 DDDs (6.1−18 g) 76 474 16.0 (12.8–20.1) 1.99 (1.58–2.52) 1.56 (1.22–1.98)
>90 DDDs (>18 g) 47 399 11.8 (8.9–15.7) 1.50 (1.11–2.02) 1.18 (0.88–1.60)
Etoricoxib
0 DDDs (0 g) 1442 16321 8.8 (8.4–9.3) 1.00 (reference) 1.00 (reference)
1−30 DDDs (0.06−1.8 g) 53 237 22.4 (17.1–29.3) 2.53 (1.92–3.34) 1.95 (1.47–2.57)
31−90 DDDs (1.9−5.4 g) 13 93 14.0 (8.1–24.1) 1.60 (0.93–2.78) 1.19 (0.69–2.07)
>90 DDDs (>5.4 g) 7 54 13.0 (6.2–27.2) 1.48 (0.70–3.11) 1.40 (0.66–2.96)

Notes: Adjusted HRs were computed after adjustment of age, sex, residence area, types of dialysis, baseline comorbidities, and opioid use.

Abbreviations: DDD, defined daily dose.